Research programme: treg therapy candidates - Baudax Bio
Latest Information Update: 19 Sep 2023
At a glance
- Originator Baudax Bio
- Class Cell therapies; Gene therapies; T lymphocyte cell therapies
- Mechanism of Action Regulatory T-lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Myasthenia gravis